IRIS Accounts Production v26.1.0.640 14482746 director 1.12.24 30.11.25 30.11.25 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh144827462024-11-30144827462025-11-30144827462024-12-012025-11-30144827462023-11-30144827462023-12-012024-11-30144827462024-11-3014482746ns15:EnglandWales2024-12-012025-11-3014482746ns14:PoundSterling2024-12-012025-11-3014482746ns10:Director12024-12-012025-11-3014482746ns10:PrivateLimitedCompanyLtd2024-12-012025-11-3014482746ns10:SmallEntities2024-12-012025-11-3014482746ns10:AuditExempt-NoAccountantsReport2024-12-012025-11-3014482746ns10:SmallCompaniesRegimeForDirectorsReport2024-12-012025-11-3014482746ns10:SmallCompaniesRegimeForAccounts2024-12-012025-11-3014482746ns10:FullAccounts2024-12-012025-11-301448274612024-12-012025-11-3014482746ns10:OrdinaryShareClass12024-12-012025-11-3014482746ns10:RegisteredOffice2024-12-012025-11-3014482746ns5:CurrentFinancialInstruments2025-11-3014482746ns5:CurrentFinancialInstruments2024-11-3014482746ns5:Non-currentFinancialInstruments2025-11-3014482746ns5:Non-currentFinancialInstruments2024-11-3014482746ns5:ShareCapital2025-11-3014482746ns5:ShareCapital2024-11-3014482746ns5:RetainedEarningsAccumulatedLosses2025-11-3014482746ns5:RetainedEarningsAccumulatedLosses2024-11-3014482746ns5:NetGoodwill2024-12-012025-11-3014482746ns5:IntangibleAssetsOtherThanGoodwill2024-12-012025-11-3014482746ns5:FurnitureFittings2024-12-012025-11-3014482746ns5:ComputerEquipment2024-12-012025-11-3014482746ns5:NetGoodwill2024-11-3014482746ns5:NetGoodwill2025-11-3014482746ns5:NetGoodwill2024-11-3014482746ns5:PlantMachinery2024-11-3014482746ns5:PlantMachinery2024-12-012025-11-3014482746ns5:PlantMachinery2025-11-3014482746ns5:PlantMachinery2024-11-3014482746ns5:WithinOneYearns5:CurrentFinancialInstruments2025-11-3014482746ns5:WithinOneYearns5:CurrentFinancialInstruments2024-11-3014482746ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-11-3014482746ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-11-3014482746ns10:OrdinaryShareClass12025-11-3014482746ns5:RetainedEarningsAccumulatedLosses2024-11-3014482746ns5:RetainedEarningsAccumulatedLosses2024-12-012025-11-30
REGISTERED NUMBER: 14482746 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 NOVEMBER 2025

FOR

CLARKE PHARMACY LIMITED

CLARKE PHARMACY LIMITED (REGISTERED NUMBER: 14482746)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 November 2025










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


CLARKE PHARMACY LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 November 2025







DIRECTOR: T Amesimeku





REGISTERED OFFICE: 1053 London Road
Leigh-On-Sea
United Kingdom
Essex
SS9 3JP





REGISTERED NUMBER: 14482746 (England and Wales)





ACCOUNTANTS: Richmond Gatehouse LLP
Thames House, 2nd floor
3 Wellington Street
London
SE18 6NY

CLARKE PHARMACY LIMITED (REGISTERED NUMBER: 14482746)

BALANCE SHEET
30 November 2025

2025 2024
Notes £    £   
FIXED ASSETS
Intangible assets 4 604,500 682,500
Tangible assets 5 9,899 13,498
614,399 695,998

CURRENT ASSETS
Stocks 39,700 40,200
Debtors 6 276,314 241,593
Cash at bank and in hand 22,659 30,304
338,673 312,097
CREDITORS
Amounts falling due within one year 7 (612,670 ) (545,933 )
NET CURRENT LIABILITIES (273,997 ) (233,836 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

340,402

462,162

CREDITORS
Amounts falling due after more than one
year

8

(577,659

)

(600,120

)
NET LIABILITIES (237,257 ) (137,958 )

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings 10 (237,357 ) (138,058 )
SHAREHOLDERS' FUNDS (237,257 ) (137,958 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 August 2026 and were signed by:



T Amesimeku - Director


CLARKE PHARMACY LIMITED (REGISTERED NUMBER: 14482746)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 November 2025


1. STATUTORY INFORMATION

Clarke Pharmacy Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 20% on cost
Computer equipment - 20% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

CLARKE PHARMACY LIMITED (REGISTERED NUMBER: 14482746)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 November 2025


4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2024
and 30 November 2025 780,000
AMORTISATION
At 1 December 2024 97,500
Charge for year 78,000
At 30 November 2025 175,500
NET BOOK VALUE
At 30 November 2025 604,500
At 30 November 2024 682,500

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 December 2024
and 30 November 2025 17,998
DEPRECIATION
At 1 December 2024 4,500
Charge for year 3,599
At 30 November 2025 8,099
NET BOOK VALUE
At 30 November 2025 9,899
At 30 November 2024 13,498

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Trade debtors 49,686 33,780
Taking control 2,147 1,109
Rent deposit 2,000 2,000
Intercompany loans 199,784 181,232
VAT 13,892 12,423
Prepayments 8,805 11,049
276,314 241,593

CLARKE PHARMACY LIMITED (REGISTERED NUMBER: 14482746)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 November 2025


7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2025 2024
£    £   
Intercompany loans 362,315 296,857
Trade Bridge loans 68,000 63,000
Trade creditors 60,935 66,626
Social security and other taxes 74 -
Wages payable 1,896 -
Directors' current accounts 118,550 118,550
Accrued expenses 900 900
612,670 545,933

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2025 2024
£    £   
Bank loans - 2-5 years 577,659 600,120

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
100 Ordinary £1 100 100

10. RESERVES
Retained
earnings
£   

At 1 December 2024 (138,058 )
Deficit for the year (99,299 )
At 30 November 2025 (237,357 )

11. ULTIMATE CONTROLLING PARTY

The controlling party is T Amesimeku.